Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Reduce” by Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned a consensus recommendation of “Reduce” from the six research firms that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $30.00.

Several brokerages recently issued reports on FMS. UBS Group cut Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of FMS opened at $23.94 on Tuesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The firm’s 50-day moving average is $24.60 and its two-hundred day moving average is $25.68. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $22.05 and a twelve month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $5.73 billion during the quarter, compared to the consensus estimate of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. As a group, sell-side analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Hennessy Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the second quarter worth approximately $11,479,000. Millennium Management LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 50.0% in the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after acquiring an additional 361,364 shares during the last quarter. Raymond James Financial Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1,508.1% during the 1st quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock worth $7,165,000 after purchasing an additional 269,857 shares during the period. Bank of America Corp DE lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% during the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after purchasing an additional 248,477 shares during the period. Finally, Pzena Investment Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% during the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after purchasing an additional 153,870 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.